Background-Epigenetic alterations may contribute to the development of atherosclerosis. In particular, DNA methylation, a reversible and highly regulated DNA modification, could influence disease onset and progression because it functions as an effector for environmental influences, including diet and lifestyle, both of which are risk factors for cardiovascular diseases. Methods and Results-To address the role of DNA methylation changes in atherosclerosis, we compared a donor-matched healthy and atherosclerotic human aorta sample using whole-genome shotgun bisulfite sequencing. We observed that the atherosclerotic portion of the aorta was hypermethylated across many genomic loci in comparison with the matched healthy counterpart. Furthermore, we defined specific loci of differential DNA methylation using a set of donor-matched aortic samples and a high-density (>450 000 CpG sites) DNA methylation microarray. The functional importance in the disease was corroborated by crossing the DNA methylation signature with the corresponding expression data of the same samples. Among the differentially methylated CpGs associated with atherosclerosis onset, we identified genes participating in endothelial and smooth muscle functions. These findings provide new clues toward a better understanding of the molecular mechanisms of atherosclerosis. Conclusions-Our data identify an atherosclerosis-specific DNA methylation profile that highlights the contribution of different genes and pathways to the disorder. Interestingly, the observed gain of DNA methylation in the atherosclerotic lesions justifies efforts to develop DNA demethylating agents for therapeutic benefit. (Circ Cardiovasc Genet. 2014;7:692-700.)
A ll cells and tissues in an organism share the same DNA sequence but can develop different functions. This conundrum was partially explained by epigenetics, 1 which represents a molecular information party independent of the genetic code. Epigenetics creates cell-specific phenotypes through the control of gene expression in a potentially heritable manner. The understanding of epigenetic alterations associated with human diseases is rapidly increasing because of the development of genome-wide technologies. 2, 3 Epigenetic profiling has begun to be of clinical value in cancer 4 and is likely to be applied to other pathologies, such as neurological 5 and cardiovascular disorders, [6] [7] [8] an example being the altered epigenomic patterns observed in human end-stage cardiomyopathy. 9
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As for atherosclerosis, its clinical complications will continue to represent a leading cause of death and disability worldwide in the next 2 decades, 10 implying that further research is necessary to unravel the molecular basis of cardiovascular diseases. Using recent technology and characterizing a broad spectrum of alterations occurring in atherosclerosis, high-throughput screening methods have to date been used in genome-wide association studies to focus on interindividual variation and genetic aberrations occurring in diseased tissue. However, relatively little attention has been paid to epigenetic alterations. Genetic predisposition is a significant factor in atherosclerosis, but the genome-wide association studies suggest that only ≈10% of cases of cardiovascular disease have a heritable component. 11, 12 Therefore, identifying the molecular mechanisms of nongenetic cardiovascular risk factors is a crucial and only partially achieved task in the field. Atherosclerosis is a multifactorial disease associated with dietary, environmental, and lifestyle risk factors. The most widely studied epigenetic mark, DNA methylation, is a flexible regulatory modification influenced by environmental and external factors, which partially overlap with known atherosclerosis nongenetic risk factors and is, therefore, potentially involved in the onset and progression of atherosclerosis. DNA methylation is a covalent modification of the DNA sequence with effect on gene expression and genomic stability. 13 DNA methylation affects transcription in a context-dependent way, wherein promoter hypermethylation mainly presents a repressive mark. However, differential DNA methylation in gene bodies and intergenic loci presents more complex mechanistic implications because it is thought to promote transcriptional elongation and to regulate gene splicing and enhancer activities. The detection of DNA methylation alterations could be a promising tool for cardiovascular risk prediction and diagnosis. Although DNA methylation alterations have been described at a few loci in atherosclerosis, 14, 15 advances in epigenomics have allowed genome-wide studies in addition to single-locus approaches. Examples are next-generation sequencing and high-density array-based techniques, which reveal DNA methylation events at base-pair resolution and with thorough coverage in regulatory regions. 3 These technologies led to the identification of significant changes in DNA methylation in various diseases, such as cancer, 16, 17 arthritis, 18 and diabetes mellitus, 19 and in physiological contexts, such as human aging. 20 Accordingly, this study aims to transfer atherosclerosis research from epigenetic single-loci studies to comprehensive epigenomic analysis by assessing disease-associated changes in an unbiased manner. We hypothesize that alterations in the DNA methylation landscape are implicated in atherosclerosis onset and progression. Herein, we present the first genomewide DNA methylation profiles of human donor-matched atherosclerotic aortic tissue pairs, acquired by exploiting whole-genome shotgun bisulfite sequencing. 21 Furthermore, we complemented the whole-genome sequencing analysis by probing a larger aortic sample with a high-coverage DNA methylation microarray 22 that determines the methylation status of >450 000 CpG sites in the human genome.
Methods

Human Vascular Samples
Post mortem donor-matched atherosclerotic and nonatherosclerotic portions of human aortas (referred to as donor-matched sample pairs) were obtained at the Bellvitge Hospital and the Clinic Hospital in Barcelona according to a protocol approved by the local ethical committee (authorization no. PR311/11). Post mortem time was between 3 and 26 hours. Atherosclerotic and normal (A and N, respectively) portions were macroscopically identified by a trained Pathology Technician. Approximately 3-cm-long segments of each portion were transferred to RNAlater (Ambion) and refrigerated. A fragment was obtained from the middle portion of each segment (either A or N), and the severity of its histological atherosclerosis was scored on the American Heart Association scale by a qualified Pathologist. The remaining samples were transferred to −80°C within 1 day of dissection. Stable, advanced (fibroatheroma or higher severity), carotid plaque samples were obtained by endarterectomy at Malmö General Hospital, Lund University, Malmö, Sweden. Atherosclerotic lesions and the underlying media (aortas) or the mere lesion (carotids) were used in all the procedures described here. The relevant donor (age and sex) and sample information for aortic and carotid specimens are shown in Table I in the Data Supplement.
Whole-Genome Bisulfite Sequencing and DNA Methylation Microarray Analyses
Genomic DNA was extracted by a conventional proteinase K (Roche) and phenol/chloroform/isoamyl alcohol (Sigma)-based protocol. For wholegenome bisulfite sequencing, 10 μg of genomic DNA were processed according to established protocols. 20 Sequencing quality was assessed using the Illumina Sequencing Analysis Viewer and the FastQC software. We ensured that the raw reads used in further analysis were within the standard parameters set by the Illumina protocol. Positional quality along the reads was checked to be QC>30, and we excluded biases toward specific motifs or GC-enriched regions in the polymerase chain reaction (PCR) amplification or hybridization. The filtered reads were aligned to the reference genome HG19 using the software Bismark and Bowtie, and the DNA methylation level of individual CpG sites was calculated after discarding multiple mapping reads. Only CpG sites containing ≥5 reads in both the normal and the atherosclerotic sample were eligible for further analysis. CpG island (CGI) mapping of whole-genome bisulfite sequencing data was done according to the annotation provided by the Ontario Cancer Institute Genomics Center. In differentially methylated region (DMR) analysis, promoters were defined as regions between positions -1500 and +500, relative to the transcription start sites.
The microarray-based DNA methylation analysis was conducted with the Infinium HumanMethylation450 BeadChip (450k array). DNA quality checks, bisulfite modification, hybridization, data normalization, statistical filtering, and β value calculation were performed as described elsewhere. 20, 22 The methylation level for each cytosine was expressed as a β value calculated as the fluorescence intensity ratio of the methylated to unmethylated versions of the probes. β Values ranged between 0 (unmethylated) and 1 (methylated). Of the 485 577 probes present in the microarray, 477 635 (98.4%) were successfully hybridized in all 49 individual samples (15A and 15N donor-paired aortic samples, 19 carotid samples). This corresponds to an average successful hybridization of >99.9% per individual sample. The annotation relating to CGIs uses the following categorization: shore, each of the 2-kb sequences flanking a CGI; shelf, each of the 2-kb sequences next to a shore; open sea, DNA not included in any of the previous sequences or in CGIs. 22 Transcription start site 200 or transcription start site 1500 indicates the region between position −200 or −1500 bp from the transcription start site, respectively. When a cytosine mapped to different genic elements because of the presence of multiple alternative transcripts, all mapping variants were counted. Functional gene annotation was performed with the DAVID database (http://david.abcc.ncifcrf.gov). Clustering was performed by Ward hierarchical clustering method, using simultaneously samples and CpGs.
Pyrosequencing and Quantitative Real-Time PCR for Candidate Genes
Pyrosequencing was performed with a Pyromark Q96 (Qiagen) as previously described. 20 Expression could be measured in only 5 post mortem aortic samples because of the difficulty of obtaining highquality RNA from these tissues. Quantitative real-time PCR (PCR) was performed in triplicate as previously described. 20 The list of primers used for the pyrosequencing methylation and quantitative real-time PCR analyses is shown in Table II in the Data Supplement. A schematic flowchart showing the source of the samples and the techniques used is shown in Figure 1 .
Statistical Analysis
In the case of 450k arrays, β values were converted to M values by a Logit transformation. 23 M values were compared using a paired (intra-aortic pair comparison) or unpaired (comparison between N aortic samples and atherosclerotic carotid samples) t test. The significance threshold in M value comparisons was a Bonferroni-corrected P<1×10 -7 , corresponding to an uncorrected P<0.05. To compare all other continuous variables, either an unpaired t test or an ANOVA with post hoc analysis was used as specified in each case. Frequencies were compared using the χ 2 test. All tests were performed using the STATISTICA software.
Results
DNA Methylomes of Atherosclerotic and Normal Aortic Tissue at Single-Nucleotide Resolution
Whole-genome shotgun bisulfite sequencing was used to obtain an unbiased insight into the epigenetic alterations in atherosclerotic aortas. In particular, we profiled the DNA methylation landscape of a grade VII atherosclerotic lesion (93A) and its adjacent unaffected normal (93N) aortic tissue obtained from a female donor (Figure 2A-2C ). The rationale for choosing that particular aortic pair was that any atherosclerosis-related DNA methylation profile would be readily detectable if the intrapair histological divergence was high. The analysis of matched tissue from the same patient avoids confounding effects of the genetic background, previously described as methylation quantitative trait loci. 24 The complete DNA methylation sequence at the single-nucleotide resolution is freely available at the Gene Expression Omnibus database: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zfeph wswcyoeotw&acc=GSE46401.
We generated 774 341 172 and 877 722 420 reads for 93A and 93N, respectively. Of these, 603 788 981 (93A) and 634 123 759 (93N) reads mapped uniquely to the reference genome HG19, corresponding to mapping efficiencies of 77.8% (93A) and 72.2% (93N). Genome wide, we achieved an average 12.5-fold (93A) and 17.9-fold (93N) coverage, enabling us to analyze 93.9% (93A) and 86.1% (93N) of all CpGs present in the reference genome.
Technically, we found that the DNA methylation levels obtained by the whole-genome bisulfite sequencing approach were highly correlated with those obtained from a DNA methylation array platform (r>0.92; Infinium HumanMethylation450 BeadChip, see below) for the 372 979 (93A) and 364 271 (93N) CpGs interrogated by the 2 techniques.
Genome wide, the atherosclerotic lesion (93A) contained more highly methylated CpGs than the matched normal tissue. A Circos representation of average methylation levels for variant CpGs in the 93A sample relative to the 93N sample is shown in Figure 2D . In particular, 93A harbored 35.16M highly methylated CpG sites (>50% methylation), 17.3% more than 93N (29.95M), and the average CpG methylation level was higher in 93A than in 93N DNA ( Figure 2E 
Identification of DMRs
Once we had identified the existence of a genome-wide aberrant DNA methylation pattern in the atherosclerotic lesion, we sought to define genome-wide tendencies of DMRs between 93A and 93N. We interrogated the nonrepetitive part of the genome for regions containing ≥5 consecutive and consistently differentially methylated CpGs and in which DNA methylation levels of the flanking CpG sites differed significantly between the 2 samples (Fisher exact test, P<0.05). We identified 54 625 DMRs genome wide, with an average size of 615 bp and containing an average of 11 informative CpGs. Consistent with the features observed at the genome-wide level, DMRs were mostly hypermethylated in the atherosclerotic lesion (93A; Figure 3A ). Both promoter-related DMRs (706, corresponding to 630 genes) and intragenic DMRs (7378, corresponding to 2304 genes) were largely hypermethylated in 93A and mapped predominantly to CG-poor regions (Figure 3B) . Hypermethylated DMRs in 93A were wider than their hypomethylated counterparts on average: 641 versus 511 bp, genome-wide (P=4.73 -58 , unpaired t test), 744 versus 352 bp in promoters (P=2.72 -8 ), and 650 versus 434 bp at intragenic loci (P=5.28 -32 ; Fisher LSD post hoc test for the latter 2 groups; Figure IA and IB in the Data Supplement).
Although methylated at low levels overall, we observed a 2-fold greater level of DNA methylation at non-CpG sites (CHG and CHH; where H=A, T, or C). We found that 0.4% and 0.2% of all CHG or CHH sites were methylated in the atherosclerotic lesion (93A) and the normal aortic tissue (93N), respectively. Focusing on intragenic and promoter DMRs (CHG-DMR), we identified 257 intragenic-related (234 genes) and 47 promoter-related (45 genes) CHG-DMRs, which shared many characteristics with CpG-defined DMRs. First, the majority (85.6%) of intragenic CHG-DMRs and all promoter counterparts were hypermethylated in 93A and mapped mostly to CG-poor regions. Second, intragenic CHG-DMRs hypermethylated in 93A were wider on average than their hypomethylated counterparts (740 and 335 bp; P=0.011, unpaired t test; Figure 1C and 1D in the Data Supplement).
We further aimed to examine DNA methylation levels in repetitive elements because long interspersed element hypomethylation in peripheral blood cell DNA has been proposed as an atherosclerosis marker. 25 Accordingly, we modified the alignment procedure and allowed multiple read mapping and subsequently assessed DNA methylation levels for repetitive elements (Repeatmasker), including transposons, repeated noncoding RNA genes, transfer RNA, and satellite DNA. Logit-transformed DNA methylation levels were averaged by chromosome. Consistent with the genome-wide trend, all DNA repeat classes were overall hypermethylated in 93A (Table III in the Data Supplement). However, a comparison of repeat subtypes revealed several differences ( Figure II in the Data Supplement). The long interspersed element subtype was the only transposon class with significantly lower DNA methylation level in 93A (Fisher LSD post hoc test, P<0.05). Alu elements stood out among Short Interspersed Nuclear Elements for being consistently hypermethylated in all analyzed chromosomes. The DNA transposon piggyBac ranked first among all repeated sequences with respect to the extent of DNA hypermethylation in 93A. Of the noncoding RNA genes, ribosomal RNAs (rRNAs) were the most hypermethylated in 93A and significantly differed from the overall hypomethylated tRNAs (P<0.05). Furthermore, subtelomeric regions were more hypermethylated in 93A than were centromeric loci (P<0.05).
DNA Methylation Map of 450 000 CpG Sites in Matched Atherosclerotic Lesions and Healthy Aortic Tissues
After describing genome-wide tendencies of DNA methylation changes in the atherosclerotic tissue, we aimed to define specific differentially methylated loci in a larger cohort of samples, using the Infinium HumanMethylation450 BeadChip (450k array), a DNA methylation array covering ≈485 000 cytosines. 22 All DNA methylation microarray data are freely available at the Gene Expression Omnibus database: http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zfephwswc yoeotw&acc=GSE46401. Importantly, despite the donor-matched nature of the analyzed sample pairs, unsupervised clustering analysis of the unfiltered 450k array data distinguished 10 of 15 atherosclerotic lesions from their matched healthy counterparts ( Figure 4A ), thereby indicating the existence of an atherosclerosis-specific DNA methylation profile that exceeded intraindividual similarities. It is noteworthy that the separation between normal and diseased specimens was achieved against a donor-matched and thus genetically paired background, corroborating the existence of consistent genomewide DNA methylation changes in atherosclerotic lesions.
We first sought specific regions with significant differences in DNA methylation profile between atherosclerotic and healthy aortic portions that were consistent in multiple atherosclerotic samples. The analysis of 15 donor-matched paired atherosclerotic and normal samples (30 samples in total), irrespective of histological grade, donor sex, and age, identified 1895 candidate differentially methylated CpG sites that were significantly altered in the diseased sample cohort (paired t test, P<10 -7 ). Importantly, DNA methylation level at these candidate differentially methylated CpGs did not significantly correlate with postmortem time points of samples collection (data not shown), which is in line with previous reported stability of DNA methylation after death. 26 Supervised clustering of the 1895 sites distinguished the majority (14 of 15) of atherosclerotic samples, highlighting the specificity of the observed DNA methylation profiles ( Figure 4B) .
To assess the robustness of the differences between the atherosclerotic and healthy aortic portions observed in the 15 discovery samples initially analyzed by microarrays, we validated 15 selected candidate differentially methylated CpGs by pyrosequencing in 24 additional donor-matched aortic pairs and 1 by conventional bisulfite sequencing in one of the initial discovery aortic pairs (16 CpG in total). The selected CpGs mapped to 10 genes known to be involved in vascular homeostasis, such as HOX family members, PDGFA, PLAT, PRRX1, and PXDN. For all pyrosequenced CpGs, the average direction of methylation change was consistent in the initial 15 aortic pairs and in the additional 24 pairs (Table IV in the Data Supplement; in the case of HOXA6, only the expression was determined, see below). In addition, we pyrosequenced the 15 selected CpGs in the original discovery in 15 aortic pairs. In all cases, direct sequencing data and the 450k array results of the initial aortic pairs were closely correlated (r≥0.81; P<0.001). In the case of MIR23b, we validated 1 CpG site by conventional bisulfite sequencing in one of the initial aortic pairs, showing a good agreement between the array and the sequencing data (Table IV in the Data Supplement) . Importantly, the DNA methylation profiles of the additional sequenced flanking CpGs were consistent with the profile of the corresponding 450k array-identified CpGs, thus confirming the consistency of the observed candidate differentially methylated CpGs. Two examples (PDGFA and PXDN) are shown in Figure 5 . Again, CpG DNA methylation levels did not significantly correlate with postmortem time even in this larger cohort (data not shown). Because atherosclerotic samples generally originated from more distal (abdominal) aortic portions than their normal counterparts, we assessed whether that the candidate differentially methylated CpG identified in the aortic samples were genuine disease-specific profiles, rather than regional epigenetic changes. To distinguish the 2 profile types, we reasoned that atherosclerosis-specific differentially methylated CpGs should display consistent profiles within paired aortic samples and between normal aortas and atherosclerotic nonaortic vessels. To this end, we analyzed 19 atherosclerotic carotid plaques on the 450k DNA methylation array platform and calculated the differences between diseased carotid and normal aortic samples for the initially identified 1895 CpGs. Applying a P<10 -7 and consistent direction of methylation change as selection criteria, we were able to validate significant atherosclerosis-specific alterations for 98.0% (1858 of 1895; observed absolute Δβ range, 0.15-0.49) of the candidate differentially methylated CpGs ( Table V in the Data Supplement). Those CpGs will be referred to as dm-CpGs. It is noteworthy that the 1858 dm-CpGs were common to samples comprising either the lesion and the underlying media (aorta) or the lesion alone (carotid artery) and are, therefore, highly specific for the lesion mass. The majority (91.3%) of atherosclerosis-specific dm-CpGs were hypermethylated in A samples and mapped to gene bodies and regions distant (>4 kbp) from CGIs (compared with the array probe distribution, χ 2 test, P<0.05; Figure 6A -6C). Genes harboring atherosclerosis-specific dm-CpGs participate in important aorta-related processes, particularly those related to endothelial cells and vascular smooth muscle cells (Table 1) . Consistently, biological processes enriched (Fisher exact test, P<0.05) among dm-CpG-harboring genes include vascular smooth muscle cell contraction (Gene Ontology) and extracellular matrix formation (KEGG; Table 2 ; Table VI in the Data Supplement for a full list of the enriched categories). Interestingly, 15 dm-CpGs were located within 100 kb of atherosclerosis-associated single-nucleotide polymorphisms 27 ( Table VII in the Data Supplement), suggesting an interplay between the risk genotype and differential DNA methylation as methylation quantitative trait loci. 24 Finally, by quantitative real-time PCR of the same donormatched aortic pairs, we attempted to define the functional consequences of the observed differential methylation. Accordingly, we analyzed 7 dm-CpG-containing genes (HOXA6, HOXA9, MIR23b, PDGFA, PLAT, PRRX1, and PXDN) presenting differential CpG methylation in gene promoters and gene bodies. All genes exhibited different transcriptional activity in atherosclerotic and normal samples ( Table IV in the Data Supplement to allow a direct comparison with DNA methylation data). Promoter CpG methylation and transcription levels were inversely associated (HOXA6 and MIR23b).
Discussion
We present the first genome-wide DNA methylation profile at single-nucleotide resolution of a donor-paired atherosclerotic and normal human aorta. Genome sequencing was complemented by profiling a larger cohort of donor-paired aortas using a high-throughput DNA methylation microarray covering >450 000 CpG sites of the human genome. Both high-density microarray and whole-genome bisulfite shotgun sequencing data consistently identified an atherosclerosisspecific epigenetic signature characterized by genome-wide DNA hypermethylation in the diseased vessel. Global DNA hypermethylation involved unique and repetitive sequences and occurred in CpG and non-CpG contexts. Differentially methylated CpGs mapped to vascular wall-specific, atherosclerosis-specific genes, and are therefore of potential mechanistic and therapeutic relevance.
Our results are consistent with the previously observed global DNA hypermethylation of blood leukocyte DNA in cardiovascular patients. 48 In particular, we replicated the Alu repeat hypermethylation described in the latter study as a potential non-tissue-specific epigenetic marker of cardiovascular disease. As further support to our data, the expression of ten-eleven translocation-2, a dioxygenase implicated in active DNA demethylation, is decreased in atherosclerotic lesions. 49, 50 Notably, global DNA hypermethylation is evoked by an atherogenic diet in rodents 51 and by selected lipoproteins in human macrophages. 52 Therefore, DNA hypermethylation emerges as an overlapping feature of the natural history of atherosclerosis and atherosclerosisrelated stimuli.
The pattern of global DNA hypermethylation observed in atherosclerotic lesions indicates a unique epigenome that is distinct from those of other human diseases both in the direction and in the magnitude of DNA methylation changes. In cancer cells for example, a global hypomethylation occurs in the context of mega-base scale blocks that lose DNA methylation. However, a focal gain of DNA methylation was frequently observed altering gene promoter profiles, including those of tumor suppressor genes. 4, 16, 17 Although at smaller magnitude, nontumoral disorders, such as systemic lupus erythematosus 18 or type 1 diabetes mellitus, 19 also revealed global DNA hypomethylation. Overall, the extent of changes in DNA methylation was comparatively lesser in atherosclerotic samples when compared with cancer. Cancer studies applying the same DNA methylation profiling technology yielded thousands of differentially methylated CpG of high magnitude in primary cancer samples. 53, 54 Interestingly, a genome-wide comparison of atherosclerotic and age-related changes 20 revealed a similar number of differentially methylated CpGs (≈600 000); however, the aged samples presented mainly hypomethylated DMR (87% hypomethylated), whereas the opposite was observed in atherosclerotic samples (80% hypermethylated). Our data indicate that despite aging being a known independent CVD risk factor, age-driven global hypomethylation of the vascular genome is not an underlying mechanism of atherosclerosis in our sample. Our study confirms that DNA methylation changes in a noncancerous context appear at specific loci, rather than presenting extensive gains or losses in large regions as occurs in tumoral samples.
In conclusion, we have identified the genome-wide DNA methylation changes and those locus-specific CpG alterations occurring during the onset and progression of human atherosclerotic lesions. These lesions present a unique epigenomic profile, compared with other blood-related diseases, neoplastic transformations, and aging, 20 whereby atherosclerosis is characterized by the prominence of DNA hypermethylation. 
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Angiotensin II signaling in cell migration 38 PDGFD The present study describes the first reference DNA methylome sequences of normal and atherosclerotic aortic human tissue, a resource that will be highly valuable to the cardiovascular and epigenetic research community. Furthermore, our analysis identified novel disease-related genes with potential value as biomarkers in future clinical applications.
